UNSPSC 51411708: Brovincamine fumarate

This classification denotes a vasodilating agent C21H25BrN2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3SNC78UTU, chemically known as eburnamenine-14-carboxylic acid, 14,15-dihydro-11-bromo-14-hydroxy-, methyl ester, (3-.alpha.,14-.beta.,16-.alpha.)-, (e)-2-butenedioate (1:1) (salt), but more generally known as brovincamine fumarate, which bears US NIH Compound Identifier 5282434.

European Medicines Agency schedules Brovincamine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00883MIG. Most nations, for tariff and trade purposes, schedule brovincamine fumarate under HS 29399900 and SITC 54149. As of Q4 2014, BROVINCAMINE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@]12CCCN3[C@@H]1C4C(C5CCC(CC5N4[C@](C2)(C(=O)OC)O)BR)CC3.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51411708 Brovincamine fumarate is a Commodity-tier code that nominally covers a specific pharmaceutical product, though recent state and local solicitations show activity across broader advanced life support and generic multi-source pharmaceutical procurement rather than brovincamine fumarate specifically. State and local governments buying under this code's broader pharmaceutical family purchase emergency medications, generic pharmaceuticals, and over-the-counter products for fire rescue departments, health and human services agencies, and multi-state cooperative purchasing programs. Issuing bodies include municipal purchasing departments (cities), state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across member jurisdictions. The work involves vendor qualification, product sourcing through authorized wholesalers, compliance with cGMP and Drug Supply Chain Security Act requirements, and management of expiration dates and shelf-life standards.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg vials, with a contract value of $40,000 and a 5 percent bid discount for Small Local Business Enterprise participation; bids closed April 8, 2026. The Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, administering the MMCAP multi-state cooperative purchasing alliance, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effective July 1, 2026.